CO5590898A2 - Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa - Google Patents
Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasaInfo
- Publication number
- CO5590898A2 CO5590898A2 CO05059491A CO05059491A CO5590898A2 CO 5590898 A2 CO5590898 A2 CO 5590898A2 CO 05059491 A CO05059491 A CO 05059491A CO 05059491 A CO05059491 A CO 05059491A CO 5590898 A2 CO5590898 A2 CO 5590898A2
- Authority
- CO
- Colombia
- Prior art keywords
- dosage form
- hmg
- inhibitor composition
- coa reductase
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Una forma de dosificación unitaria que comprende:(a) una composición de inhibidor de la proteína de transferencia de ésteres de colesterilo, comprendiendo dicha composición de inhibidor de la proteína de transferencia de ésteres de colesterilo una dispersión sólida amorfa de un inhibidor de la proteína de transferencia de ésteres de colesterilo y un polímero ácido potenciador de la concentración; y (b) una composición de inhibidor de la HMG-CoA-reductasa que comprende un inhibidor de la HMG-CoA-reductasa;en la que dicha dispersión sólida amorfa y dicho inhibidor de la HMG CoA-reductasa están sustancialmente separados entre sí en dicha forma de dosificación.2.- La forma de dosificación unitaria de la reivindicación 1, en la que dicha forma de dosificación comprende una pluralidad de gránulos de dicha composición de inhibidor de la proteína de transferencia de ésteres de colesterilo y una pluralidad de gránulos de dicha composición de inhibidor de la HMG-CoA-reductasa.3.- La forma de dosificación unitaria de la reivindicación 1, en la que dicha forma de dosificación comprende al menos dos capas, comprendiendo al menos una de dichas capas dicha composición de inhibidor de la proteína de transferencia de ésteres de colesterilo y comprendiendo otra de dichas capas dicha composición de inhibidor de la HMG-CoA-reductasa.4.- La forma de dosificación unitaria de la reivindicación 1, en la que a menos una de dicha composición de inhibidor de la proteína de transferencia de ésteres de colesterilo y dicha composición de inhibidor de la HMG-CoA-reductasa, tiene un revestimiento no ácido.5.- La forma de dosificación unitaria de la reivindicación 1, en la que dicha forma de dosificación se selecciona del grupo que consta de un comprimido, comprimido oblongo, píldora, cápsula, polvo, y un kit que comprende uno o más comprimidos, comprimidos oblongos, píldoras, cápsulas, sobres, polvos, o soluciones destinadas a tomarse juntas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43534502P | 2002-12-20 | 2002-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5590898A2 true CO5590898A2 (es) | 2005-12-30 |
Family
ID=32682223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05059491A CO5590898A2 (es) | 2002-12-20 | 2005-06-17 | Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa |
Country Status (24)
Country | Link |
---|---|
US (1) | US7897175B2 (es) |
EP (1) | EP1581210B1 (es) |
JP (1) | JP2006512359A (es) |
KR (1) | KR20050088190A (es) |
CN (1) | CN1728995A (es) |
AR (1) | AR042534A1 (es) |
AT (1) | ATE389396T1 (es) |
AU (1) | AU2003286372A1 (es) |
BR (1) | BR0317593A (es) |
CA (1) | CA2509688A1 (es) |
CO (1) | CO5590898A2 (es) |
DE (1) | DE60319877T2 (es) |
ES (1) | ES2300628T3 (es) |
GT (1) | GT200300295A (es) |
IL (1) | IL169090A0 (es) |
NL (1) | NL1025070C (es) |
NO (1) | NO20052779L (es) |
PE (1) | PE20040970A1 (es) |
PL (1) | PL377606A1 (es) |
RU (1) | RU2005119176A (es) |
TW (1) | TW200420301A (es) |
UY (1) | UY28134A1 (es) |
WO (1) | WO2004056359A1 (es) |
ZA (1) | ZA200504123B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CA2455288A1 (en) * | 2001-06-21 | 2003-01-03 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
CA2450748A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
BRPI0516772A (pt) * | 2004-10-25 | 2008-09-23 | Japan Tobacco Inc | formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação |
AP2007003979A0 (en) * | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8828438B2 (en) | 2005-05-31 | 2014-09-09 | Bend Research, Inc. | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase |
CA2618255C (en) | 2005-08-08 | 2015-05-26 | Abbott Gmbh & Co. Kg | Itraconazole compositions with improved bioavailability |
JP2009504590A (ja) * | 2005-08-08 | 2009-02-05 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 改善された生物学的利用能をもつ剤型 |
DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
KR100791256B1 (ko) * | 2006-03-17 | 2008-01-03 | 주식회사 대웅제약 | 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물 |
US20070269503A1 (en) * | 2006-05-16 | 2007-11-22 | James Walter Burgess | Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof |
AU2007300071A1 (en) * | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
WO2008065506A2 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein |
AR071706A1 (es) * | 2008-05-15 | 2010-07-07 | Otsuka Pharma Co Ltd | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US8877221B2 (en) | 2010-10-27 | 2014-11-04 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same |
US9107983B2 (en) | 2010-10-27 | 2015-08-18 | Warsaw Orthopedic, Inc. | Osteoconductive matrices comprising statins |
CN103200935A (zh) | 2010-11-04 | 2013-07-10 | 霍夫曼-拉罗奇有限公司 | 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物 |
KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
WO2012170417A2 (en) | 2011-06-06 | 2012-12-13 | Warsaw Orthopedic, Inc. | Methods and compositions to enhance bone growth comprising a statin |
US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
MA40590A (fr) * | 2014-08-28 | 2017-07-05 | Dezima Pharma B V | Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase |
JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
EP0680320B1 (en) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
DK0828495T3 (da) | 1995-06-01 | 2003-02-24 | Searle & Co | Misoprostolholdige faste stabiliserede dispersioner |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
ATE250929T1 (de) * | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
AU2157400A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
EP1970052A2 (en) * | 1999-02-09 | 2008-09-17 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
WO2001093860A1 (en) * | 2000-06-09 | 2001-12-13 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
HUP0303083A3 (en) * | 2000-08-15 | 2005-05-30 | Pfizer Prod Inc | Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use |
US20020077348A1 (en) | 2000-11-21 | 2002-06-20 | Dean Herbert M. | Dosage unit for cardioprotection |
US20040235935A1 (en) * | 2001-06-12 | 2004-11-25 | Francis Vanderbist | Oral pharmaceutical composition containing a statin derivative |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
CA2508840A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
-
2003
- 2003-12-12 JP JP2004561902A patent/JP2006512359A/ja active Pending
- 2003-12-12 ES ES03777117T patent/ES2300628T3/es not_active Expired - Lifetime
- 2003-12-12 PL PL377606A patent/PL377606A1/pl not_active Application Discontinuation
- 2003-12-12 CN CNA2003801069589A patent/CN1728995A/zh active Pending
- 2003-12-12 AU AU2003286372A patent/AU2003286372A1/en not_active Abandoned
- 2003-12-12 KR KR1020057011269A patent/KR20050088190A/ko not_active Application Discontinuation
- 2003-12-12 BR BR0317593-6A patent/BR0317593A/pt not_active IP Right Cessation
- 2003-12-12 CA CA002509688A patent/CA2509688A1/en not_active Abandoned
- 2003-12-12 WO PCT/IB2003/006087 patent/WO2004056359A1/en active IP Right Grant
- 2003-12-12 DE DE60319877T patent/DE60319877T2/de not_active Revoked
- 2003-12-12 EP EP03777117A patent/EP1581210B1/en not_active Revoked
- 2003-12-12 RU RU2005119176/15A patent/RU2005119176A/ru not_active Application Discontinuation
- 2003-12-12 AT AT03777117T patent/ATE389396T1/de not_active IP Right Cessation
- 2003-12-18 NL NL1025070A patent/NL1025070C/nl not_active IP Right Cessation
- 2003-12-18 TW TW092135977A patent/TW200420301A/zh unknown
- 2003-12-18 US US10/739,567 patent/US7897175B2/en not_active Expired - Fee Related
- 2003-12-18 AR ARP030104713A patent/AR042534A1/es unknown
- 2003-12-18 UY UY28134A patent/UY28134A1/es not_active Application Discontinuation
- 2003-12-19 GT GT200300295A patent/GT200300295A/es unknown
-
2004
- 2004-01-05 PE PE2004000021A patent/PE20040970A1/es not_active Application Discontinuation
-
2005
- 2005-05-20 ZA ZA200504123A patent/ZA200504123B/en unknown
- 2005-06-08 NO NO20052779A patent/NO20052779L/no not_active Application Discontinuation
- 2005-06-09 IL IL169090A patent/IL169090A0/en unknown
- 2005-06-17 CO CO05059491A patent/CO5590898A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050088190A (ko) | 2005-09-02 |
UY28134A1 (es) | 2004-07-30 |
WO2004056359A1 (en) | 2004-07-08 |
AU2003286372A1 (en) | 2004-07-14 |
NL1025070C (nl) | 2010-04-06 |
DE60319877T2 (de) | 2009-04-30 |
BR0317593A (pt) | 2005-11-22 |
CN1728995A (zh) | 2006-02-01 |
NO20052779D0 (no) | 2005-06-08 |
IL169090A0 (en) | 2007-07-04 |
DE60319877D1 (de) | 2008-04-30 |
JP2006512359A (ja) | 2006-04-13 |
PL377606A1 (pl) | 2006-02-06 |
CA2509688A1 (en) | 2004-07-08 |
ATE389396T1 (de) | 2008-04-15 |
ES2300628T3 (es) | 2008-06-16 |
RU2005119176A (ru) | 2006-01-20 |
NO20052779L (no) | 2005-08-25 |
US7897175B2 (en) | 2011-03-01 |
US20040197398A1 (en) | 2004-10-07 |
PE20040970A1 (es) | 2004-12-14 |
EP1581210A1 (en) | 2005-10-05 |
NL1025070A1 (nl) | 2004-06-22 |
AR042534A1 (es) | 2005-06-22 |
TW200420301A (en) | 2004-10-16 |
EP1581210B1 (en) | 2008-03-19 |
ZA200504123B (en) | 2006-02-22 |
GT200300295A (es) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5590898A2 (es) | Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa | |
ATE396712T1 (de) | Pharmazeutische zubereitung zur modifizierten freisetzung | |
EA200970267A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ МНОЖЕСТВО МИНИ-ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР ФАКТОРА Xa | |
SG164281A1 (en) | Controlled release preparation | |
MX2008012731A (es) | Tabletas de paracetamol de liberacion rapida. | |
ATE329579T1 (de) | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin | |
EA200100024A1 (ru) | Состав таблетки с делавирдином | |
TR200001810A2 (tr) | Hemen Eriyen Oral Dozaj Formülasyonu. | |
TW200510001A (en) | Dual drug dosage forms with improved separation of drugs | |
BRPI0509971A (pt) | uma forma de dosagem farmacêutica, comprimido e método de preparação | |
WO2004105727A3 (en) | Stabilized pharmaceutical product | |
ZA200701443B (en) | Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle | |
ATE304844T1 (de) | Entzündungshemmende pharmazeutische formulierungen | |
ZA200506992B (en) | Fibrate tablet and method for the production thereof | |
WO2004062552A3 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
TR200102802T2 (tr) | Tabletlerin direk kompresyonla üretiminde, yüksek L-karnitin-alkanoil L-karnitinli granülat | |
ATE533834T1 (de) | Mehrfasige wäschebehandlungstabletten | |
AU2003227051A1 (en) | Pack for medicine in capsule, pill or similar form | |
WO2004010974A3 (en) | Gelatin capsule exhibiting reduced cross-linking | |
DE60001717D1 (de) | Mikrokapseln mit verzögerter freisetzung von wirkstoffen | |
DE69917658D1 (de) | Micronisierte pharmazeutische zusammensetzungen | |
AU2003245774A1 (en) | Pharmaceutical dosage form bearing pregnancy-friendly indicia | |
WO2008038155A3 (en) | Controlled-release pharmaceutical tablets | |
CA2473718A1 (en) | Immediate-release pharmaceutical dosage form comprising polymorphous tibolone | |
MY146552A (en) | Retard formulation for pralnacasan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |